Typhoid Clinical Trial
Official title:
A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC-ssaV-) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility. The vaccine will be delivered as a single oral dose to healthy, typhoid vaccine-naïve adults.
This was a randomised, double-blind, placebo-controlled, single dose, dose escalation study with 4 dosing cohorts. Within each cohort, 45 evaluable subjects were planned (36 subjects receiving M01ZH09, 9 receiving placebo). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03312699 -
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
|
Phase 1 | |
Completed |
NCT01405521 -
Understanding Typhoid Disease After Vaccination
|
Phase 2 | |
Completed |
NCT00125047 -
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
|
Phase 4 | |
Completed |
NCT00131833 -
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
|
Phase 4 | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
Active, not recruiting |
NCT03933098 -
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT00125008 -
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
|
Phase 4 | |
Recruiting |
NCT04878549 -
Transcriptomic Responses for the Identification of Pathogens
|
||
Completed |
NCT02645032 -
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
|
Phase 1 | |
Recruiting |
NCT05475379 -
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh
|
Phase 1/Phase 2 | |
Completed |
NCT04204096 -
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
|
Phase 3 | |
Active, not recruiting |
NCT03299426 -
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
|
Phase 3 | |
Completed |
NCT01019083 -
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
|
Phase 1/Phase 2 | |
Completed |
NCT03614533 -
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
|
Phase 2 | |
Completed |
NCT00131820 -
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
|
Phase 4 | |
Completed |
NCT03527355 -
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
|
Phase 2 |